Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Nuvectis Pharma, Inc. Common Stock

NVCT

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Last trade $19.28
Day change +$0.17 (+0.89%)
Day range $18.82 – $19.44
Volume 100,948
Market cap $657M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$657.17M
Price / earnings
—
Price / book
5.19×
Price / sales
—
EV / sales
—
EV / EBITDA
-9.91×

Profitability

Earnings per share
-$1.47
Return on assets
-35.82%
Return on equity
-39.84%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
9.92×
Quick ratio
9.92×
Cash ratio
9.91×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.29M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for NVCT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.68M$2.51M$2.15M$2.53M$2.02M$2.98M$1.89M$1.95M
Research and development$27.37M$4.68M$4.11M$5.09M$5.77M$3.61M$3.68M$4.5M
Total operating expenses$31.05M$7.2M$6.26M$7.62M$7.79M$6.6M$5.57M$6.45M
Operating income-$31.05M-$7.2M-$6.26M-$7.62M-$7.79M-$6.6M-$5.57M-$6.45M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$30.07M-$7.02M-$6.05M-$7.31M-$7.46M-$6.33M-$5.33M-$6.25M
Income taxes$0$0$0$0$0$0$0$0
Net income-$30.07M-$7.02M-$6.05M-$7.31M-$7.46M-$6.33M-$5.33M-$6.25M
Net income attributable to common shareholders-$30.07M-$7.02M-$6.05M-$7.31M-$9.89M-$6.33M-$5.33M-$6.25M
EBITDA-$31.05M-$7.2M-$6.26M-$7.62M-$7.79M-$6.6M-$5.57M-$6.45M
Basic earnings per share-$1.02-$0.30-$0.26-$0.31-$0.44-$0.30-$0.27-$0.35
Diluted earnings per share-$1.02-$0.30-$0.26-$0.31-$0.44-$0.30-$0.27-$0.35

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026

Nuvectis Pharma announced it will host a conference call on November 4, 2026 at 8:00 AM ET to discuss Q3 2026 business progress and financial results. The clinical-stage biopharmaceutical company is focused on developing therapies for complement-related conditions and oncology, with lead candidate NXP100 (ciprocopan) recently approved in China for PNH treatment.

GlobeNewswire Inc.

Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock

Nuvectis Pharma (Nasdaq: NVCT), a clinical-stage biopharmaceutical company, announced the pricing of an underwritten public offering of 5 million shares at $20.00 per share, generating $100 million in gross proceeds. The company plans to use the funds to advance development of its pipeline candidates NXP100, NXP200, and NXP900, hire personnel, and cover operational expenses. The offering is expected to close on July 1, 2026.

GlobeNewswire Inc.

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting

Nuvectis Pharma announced three poster presentations for its clinical-stage drug NXP900, a first-in-class YES1/SRC inhibitor, at the 2026 AACR Meeting in San Diego (April 17-22). The presentations will showcase NXP900's synergy with KRAS inhibitors in NSCLC models, strategies to overcome drug resistance in cholangiocarcinoma, and its potential to restore antitumor immunity by targeting myeloid-derived suppressor cells.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.